Acura Pharmaceuticals Provides Update on Opioid Product Licensed to Pfizer; OXECTA Tablets CII Now Commercially Available

Acura Pharmaceuticals, Inc.

announced today that it has been informed by Pfizer, Inc.

that OXECTA® (oxycodone HCl, USP) Tablets CII is now commercially available. OXECTA, which utilizes Acura's AVERSION® Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg dosage strengths. "The commercial availability of OXECTA is an important milestone and we are pleased Pfizer continues to advance the commercialization plan for OXECTA," said Bob Jones, chief executive officer of Acura Pharmaceuticals. Acura has exclusively licensed the AVERSION Technology to Pfizer in the United States, Canada and Mexico for use in four opioid-based pain products. Acura receives tiered royalties ranging from 5% to 25% on net sales (gross sales less discounts, if any) of OXECTA commencing on the first anniversary of the first commercial sale of OXECTA. Pfizer has an option to license the use of the AVERSION technology with additional opioids.